Evidence map›Paper›PMID 31671257›Full record

ArticleCPT: pharmacometrics & systems pharmacology2019

A Citrulline-Based Translational Population System Toxicology Model for Gastrointestinal-Related Adverse Events Associated With Anticancer Treatments.

Tomoki Yoneyama, Kojo Abdul-Hadi, Adam Brown, Emily Guan, Matt Wagoner, Andy Z X Zhu

Open access · goldAbstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Tomoki YoneyamaQuantitative Translational Sciences, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.ORCID 0000-0002-2207-3505
Kojo Abdul-HadiGlobal Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Adam BrownGlobal Drug Safety Research and Evaluation, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Emily GuanGlobal Drug Safety Research and Evaluation, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Matt WagonerGlobal Drug Safety Research and Evaluation, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Andy Z X ZhuQuantitative Translational Sciences, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Takeda (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal (GI)-related adverse events (AEs) are commonly observed in the clinic during cancer treatments. Citrulline is a potentially translatable biomarker of GI AEs. In this study, irinotecan-induced citrulline changes were studied for a range of doses and schedules in rats. A translational system toxicology model for GI AEs using citrulline was then developed based on new experimental data and parameters from a literature intestinal cell dynamic model. With the addition of feedback-development and tolerance-development mechanisms, the model well captured the plasma citrulline profiles after irinotecan treatment in rats. Subsequently, the model was translated to humans and predicted the observed GI AE dynamics in humans including dose-scheduling effect using the cytotoxic and feedback parameters estimated in rats with slight calibrations. This translational toxicology model could be used for other antineoplastic drugs to simulate various clinical dosing scenarios before human studies and mitigate potential GI AEs.

Indexed as

AnimalsAntineoplastic AgentsCitrullineDisease Models, AnimalGastrointestinal TractHumansIrinotecanRatsToxicity TestsTranslational Research, BiomedicalAntineoplastic AgentsCitrullineIrinotecan

Identifiers

PMID31671257
PMCPMC6930863
OpenAlexW2982302150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.